Quick Answer
Amphastar Pharmaceuticals, Inc. reported Total Revenue of $719.89 million for fiscal year 2025.
Amphastar Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $719.89M -1.7% |
$731.97M +13.6% |
$644.39M +29.1% |
$498.99M +14.0% |
$437.77M +25.1% |
$349.85M +8.5% |
| Net Income | $98.09M -38.5% |
$159.52M +16.0% |
$137.54M +50.5% |
$91.39M +47.1% |
$62.12M +4327.4% |
$1.40M -97.1% |
| Diluted EPS | $2.03 -33.7% |
$3.06 +17.7% |
$2.60 +49.4% |
$1.74 +39.2% |
$1.25 +4066.7% |
$0.03 -96.9% |
| Total Assets | $1.63B +3.3% |
$1.58B +4.3% |
$1.51B +103.9% |
$741.99M +10.5% |
$671.53M +6.4% |
$631.24M +7.5% |
| Cash and Equivalents | $170.18M +12.2% |
$151.61M +5.1% |
$144.30M -7.6% |
$156.10M +23.5% |
$126.35M +36.4% |
$92.64M +25.7% |
| Stockholders Equity | $788.80M +7.7% |
$732.30M +14.5% |
$639.42M +21.0% |
$528.66M +18.7% |
$445.52M +10.7% |
$402.31M +5.5% |
| R&D Expense | $85.84M +16.1% |
$73.91M +0.2% |
$73.74M -1.4% |
$74.77M +22.7% |
$60.93M -9.4% |
$67.23M -2.4% |
| Operating Income | $140.40M -31.7% |
$205.42M +4.3% |
$196.99M +83.2% |
$107.50M +53.8% |
$69.89M +538.0% |
$10.95M +28187.2% |
| Gross Profit | $356.06M -4.8% |
$373.86M +6.5% |
$351.12M +41.1% |
$248.86M +24.6% |
$199.74M +39.3% |
$143.34M +8.7% |
| Shares Outstanding | 45.65M -4.1% |
47.62M -0.9% |
48.07M -0.1% |
48.11M +0.8% |
47.71M +0.5% |
47.50M +2.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $191.84M | +0.3% | +10.0% |
| Net Income | September 30, 2025 | $17.35M | -57.1% | -44.1% |
| Diluted EPS | September 30, 2025 | $0.37 | -52.6% | -42.2% |
| Total Assets | September 30, 2025 | $1.67B | +7.8% | +3.2% |
| Cash and Equivalents | September 30, 2025 | $216.26M | +12.6% | +15.2% |
| Stockholders Equity | September 30, 2025 | $776.75M | +6.7% | +2.5% |
| R&D Expense | September 30, 2025 | $22.35M | +6.1% | +11.3% |
| Operating Income | September 30, 2025 | $25.32M | -55.6% | -40.0% |
| Gross Profit | September 30, 2025 | $98.65M | -3.2% | +14.1% |
| Shares Outstanding | September 30, 2025 | 46.35M | -4.2% | -0.3% |
- Amphastar Pharmaceuticals, Inc. reported Total Revenue of $719.89 million for fiscal year 2025.
- Amphastar Pharmaceuticals, Inc. showed a decrease of -1.7% in Total Revenue compared to the prior fiscal year.
- Amphastar Pharmaceuticals, Inc. reported Net Income of $98.09 million for fiscal year 2025.
- Amphastar Pharmaceuticals, Inc. showed a decrease of -38.5% in Net Income compared to the prior fiscal year.
- Amphastar Pharmaceuticals, Inc. reported Diluted EPS of $2.03 per share for fiscal year 2025.
- Amphastar Pharmaceuticals, Inc. showed a decrease of -33.7% in Diluted EPS compared to the prior fiscal year.
- Amphastar Pharmaceuticals, Inc. reported Total Assets of $1.63 billion for fiscal year 2025.
- Amphastar Pharmaceuticals, Inc. showed an increase of +3.3% in Total Assets compared to the prior fiscal year.
- Amphastar Pharmaceuticals, Inc. reported Cash and Equivalents of $170.18 million for fiscal year 2025.
- Amphastar Pharmaceuticals, Inc. showed an increase of +12.2% in Cash and Equivalents compared to the prior fiscal year.
- Amphastar Pharmaceuticals, Inc. reported Stockholders Equity of $788.80 million for fiscal year 2025.
- Amphastar Pharmaceuticals, Inc. showed an increase of +7.7% in Stockholders Equity compared to the prior fiscal year.
- Amphastar Pharmaceuticals, Inc. reported R&D Expense of $85.84 million for fiscal year 2025.
- Amphastar Pharmaceuticals, Inc. showed an increase of +16.1% in R&D Expense compared to the prior fiscal year.
- Amphastar Pharmaceuticals, Inc. reported Operating Income of $140.40 million for fiscal year 2025.
- Amphastar Pharmaceuticals, Inc. showed a decrease of -31.7% in Operating Income compared to the prior fiscal year.
- Amphastar Pharmaceuticals, Inc. reported Gross Profit of $356.06 million for fiscal year 2025.
- Amphastar Pharmaceuticals, Inc. showed a decrease of -4.8% in Gross Profit compared to the prior fiscal year.
- Amphastar Pharmaceuticals, Inc. reported Shares Outstanding of 45.65 million shares for fiscal year 2025.
- Amphastar Pharmaceuticals, Inc. showed a decrease of -4.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: